An analysis by a state insurance trade group forecast that paying for new HCV treatments could cost taxpayers billions of dollars.
Three panelists from the FDA's advisory panel offered their views on the panel's decision to recommend approval of Sprout Pharmaceuticals' flibanserin
Groups urge disclosure of payments to nurse practitioners and physician assistants; Horizon seeks $3-billion acquisition of Depomed; Sanofi closes $245-million agreement to buy priority-review voucher
The finalists in each of the 32 categories for this year's MM&M Awards are revealed here.
The Boston-based biotech saw its novel cystic-fibrosis drug, Orkambi, receive approval, but it could face an uphill climb in convincing payers to pay for it.
The health insurer will offer Fit4D's diabetes coaching program to its members after testing the program during a pilot last year.
Dr. Stephen Ostroff took over as the FDA's acting commissioner when Dr. Margaret Hamburg stepped down in March.
Vertex's cystic-fibrosis drug scores approval; Bloomberg Business analysis finds competitive product categories attract the most marketing dollars; Allergan makes a deal with developmental medical-device company
Please open the PDF (named Index) below for a complete listing from our July 2015 issue
North American healthcare agencies and the holding companies that own them
- Insurance trade group says new HCV drugs could cost California billions
- FDA advisory panelists describe decision to recommend approval of "female Viagra"
- Five things for pharma marketers to know: Tuesday, July 7
- Curious if you're a finalist in the MM&M Awards? Find out now
- Vertex's Orkambi nabs FDA approval but may face payer backlash